Harvest Portfolios Group Inc. Boosts Position in Boston Scientific Corporation $BSX

Harvest Portfolios Group Inc. lifted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 6.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 597,341 shares of the medical equipment provider’s stock after acquiring an additional 34,598 shares during the period. Harvest Portfolios Group Inc.’s holdings in Boston Scientific were worth $56,956,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of BSX. Murphy & Mullick Capital Management Corp raised its holdings in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares during the period. FWL Investment Management LLC purchased a new position in shares of Boston Scientific during the 2nd quarter worth $26,000. United Community Bank raised its holdings in shares of Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 147 shares during the period. Colonial Trust Co SC raised its holdings in shares of Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 231 shares during the period. Finally, Bangor Savings Bank raised its holdings in shares of Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 142 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. JPMorgan Chase & Co. reduced their price target on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Weiss Ratings downgraded Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, May 13th. Mizuho cut their price objective on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a research report on Monday, April 13th. Wells Fargo & Company cut their price objective on Boston Scientific from $94.00 to $75.00 and set an “overweight” rating for the company in a research report on Thursday, April 23rd. Finally, Jefferies Financial Group cut their price objective on Boston Scientific from $110.00 to $100.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $92.71.

Boston Scientific Stock Performance

NYSE BSX opened at $56.78 on Wednesday. Boston Scientific Corporation has a 1-year low of $52.52 and a 1-year high of $109.50. The company has a market cap of $84.39 billion, a P/E ratio of 23.76, a P/E/G ratio of 1.02 and a beta of 0.62. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The stock has a 50-day moving average of $62.77 and a two-hundred day moving average of $81.02.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. During the same period in the previous year, the company posted $0.75 earnings per share. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 3.38 EPS for the current year.

Boston Scientific declared that its Board of Directors has approved a share buyback program on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s board believes its stock is undervalued.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported positive pivotal FRACTURE trial results for its investigational SEISMIQ 4CE coronary intravascular lithotripsy catheter, with the device meeting both primary safety and effectiveness endpoints in patients with severely calcified coronary artery disease. The data should help support an FDA filing and strengthens the company’s growth outlook in interventional cardiology. Article Title
• Positive Sentiment: The company also announced a $2 billion accelerated share repurchase program, which signals confidence from management and should help reduce share count, providing a near-term earnings-per-share tailwind. Article Title
• Positive Sentiment: Boston Scientific said it invested $1.5 billion in MiRus for about a 34% stake and obtained an option to buy the startup’s TAVR business, giving BSX a potential path into a large structural heart market and another long-term growth catalyst. Article Title
• Neutral Sentiment: Analyst commentary remained mostly constructive, with several firms reiterating buy/outperform ratings even as some price targets were trimmed, suggesting Wall Street still sees upside despite a lower valuation framework. Article Title
• Neutral Sentiment: Healthcare sector strength also provided a mild tailwind, with the broader group rising late in the session. Article Title
• Negative Sentiment: Offsetting the positives, Robert W. Baird and Bank of America both lowered price targets on BSX, which may temper enthusiasm even though both firms kept constructive ratings. Article Title

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.